SCHEMBL3540318

SCHEMBL3540318

CN1CCN(c2ccc3nc(-c4n[nH]c5cc(-c6nc7ccccc7[nH]6)ccc45)[nH]c3c2)CC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.80
FLT1 P17948 4/20 0.80
CDK2 P24941 6/20 0.66
CDK4 P11802 3/20 0.66
CCNA2 P20248 3/20 0.66
CCND1 P24385 3/20 0.66
CCND3 P30281 3/20 0.66
TOP1 P11387 3/20 0.62
TOP2A P11388 3/20 0.62
ALDH1A1 P00352 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
HPGD P15428 1/20 0.62
HSD17B10 Q99714 1/20 0.62
TERT O14746 2/20 0.59
MEN1 O00255 1/20 0.57
SLCO2B1 O94956 1/20 0.57
GLA P06280 1/20 0.57
MAPT P10636 1/20 0.57
RECQL P46063 1/20 0.57
BLM P54132 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542673 0.94 FGFR1 (0.70) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL14906539 0.94 FGFR1 (0.90) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL15868925 0.92 FGFR1 (0.80) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL3542101 0.92 FGFR1 (0.80) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL3537572 0.90 FGFR1 (0.64) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL3536819 0.87 FGFR1 (0.71) FGFR1FLT1TOP1TOP2AALDH1A1
SCHEMBL14892593 0.86 FGFR1 (0.76) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL3536992 0.86 FGFR1 (0.73) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL3541759 0.86 FGFR1 (0.58) FGFR1FLT1CDK2CDK4CCNA2
SCHEMBL3539470 0.84 FGFR1 (0.56) FGFR1FLT1CDK2CDK4CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885CDK2 609/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885CDK2 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.